Scholarlink

Objective <p>To determine current prescribing practice of acid-suppressive therapy in preterm infants admitted to the neonatal intensive care unit (NICU).</p> Study design <p>Cohort study of infants 22 to 27 weeks gestation discharged from Pediatrix Medical Group NICUs between 2015 and 2020.</p> Results <p>Of 13,735 infants meeting inclusion criteria, 11% were exposed to acid-suppressive therapy during hospitalization, with 3% of those treated on the day of discharge. Exposed infants had lower birthweights (BW) (<i>p</i> &lt; 0.001). 42% of infants exposed to acid-suppressive therapy received a gastroesophageal reflux disease (GERD) diagnosis (<i>p</i> &lt; 0.001). Median (25th–75th percentile) duration of use was 7 (4–14) days. Use decreased overall during the 5-year period (<i>p</i> &lt; 0.001).</p> Conclusion <p>Acid-suppressive therapies are used commonly in preterm infants and receipt is higher in infants with lower BWs. Use has significantly decreased over time and appears to be targeted, with many infants treated for one-week courses and without a diagnosis of GERD.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Medical treatment of gastroesophageal reflux in the neonatal intensive care unit: current practice

  • 期刊论文

  • 发表日期：

    2025年2月22日

查看全文
  • Chelsea Lockyear,
  • Ashley Stark,
  • Henry P. Foote,
  • Anthony Agyeman,
  • Manar Bouleqcha,
  • Noam Cohen,
  • Clare Matusevich,
  • Ansley Pantsari,
  • Shuyan Wang,
  • Sharla Rent,
  • William Malcolm,
  • Veeral N. Tolia,
  • Rachel G. Greenberg,
  • Samia Aleem

摘要

Objective

To determine current prescribing practice of acid-suppressive therapy in preterm infants admitted to the neonatal intensive care unit (NICU).

Study design

Cohort study of infants 22 to 27 weeks gestation discharged from Pediatrix Medical Group NICUs between 2015 and 2020.

Results

Of 13,735 infants meeting inclusion criteria, 11% were exposed to acid-suppressive therapy during hospitalization, with 3% of those treated on the day of discharge. Exposed infants had lower birthweights (BW) (p < 0.001). 42% of infants exposed to acid-suppressive therapy received a gastroesophageal reflux disease (GERD) diagnosis (p < 0.001). Median (25th–75th percentile) duration of use was 7 (4–14) days. Use decreased overall during the 5-year period (p < 0.001).

Conclusion

Acid-suppressive therapies are used commonly in preterm infants and receipt is higher in infants with lower BWs. Use has significantly decreased over time and appears to be targeted, with many infants treated for one-week courses and without a diagnosis of GERD.